Table 1. Baseline characteristics of... | American Society of Hematology

Table 1.

Baseline characteristics of study and reference patients with FL undergoing high-dose therapy and ASCT

	HD-RIT, n = 27			C-HDT, n = 98
Characteristic	No.	%	No.	%	P
Bulk at Tx
Less than 5 cm	19	70	77	79	.1
5 cm or more	8	30	14	14
Unknown	0	0	7	7
Male sex	15	56	61	62	.53
Median age, y (range)	46 (24-59)		49 (30-59)		.06
Stages III/IV at Tx	26	96	89	91	.35
LDH at Tx
Elevated	11	41	17	17	.03
Normal	16	59	69	70
Unknown	0		12	12
Age-adjusted IPI score
0	1	4	8	8
1	15	56	62	63	.019
2	11	41	16	16	(0-1 vs 2-3)
3	0	0	0	0
Unknown			12	12
Transformed to DLBCL	4	15	8	8	.3
Documented splenomegaly	7	26	14	14	.15
Median no. prior regimens	2(1-6)		2(1-11)
	mean = 2.85		mean = 2.32
3 or more prior regimens	13	48	33	34	.17
Prior anthracycline	20	74	86	87	.08
Prior platinum	10	37	34	35	.82
Prior radiation	2	7	19	19	.24
Chemosensitive disease	16	59	66	67	.57
Chemoresistant/primary refractory at Tx	2	7	13	13
Untreated relapse at Tx	9	33	19	19

	HD-RIT, n = 27			C-HDT, n = 98
Characteristic	No.	%	No.	%	P
Bulk at Tx
Less than 5 cm	19	70	77	79	.1
5 cm or more	8	30	14	14
Unknown	0	0	7	7
Male sex	15	56	61	62	.53
Median age, y (range)	46 (24-59)		49 (30-59)		.06
Stages III/IV at Tx	26	96	89	91	.35
LDH at Tx
Elevated	11	41	17	17	.03
Normal	16	59	69	70
Unknown	0		12	12
Age-adjusted IPI score
0	1	4	8	8
1	15	56	62	63	.019
2	11	41	16	16	(0-1 vs 2-3)
3	0	0	0	0
Unknown			12	12
Transformed to DLBCL	4	15	8	8	.3
Documented splenomegaly	7	26	14	14	.15
Median no. prior regimens	2(1-6)		2(1-11)
	mean = 2.85		mean = 2.32
3 or more prior regimens	13	48	33	34	.17
Prior anthracycline	20	74	86	87	.08
Prior platinum	10	37	34	35	.82
Prior radiation	2	7	19	19	.24
Chemosensitive disease	16	59	66	67	.57
Chemoresistant/primary refractory at Tx	2	7	13	13
Untreated relapse at Tx	9	33	19	19

Tx indicates transplantation; DLBCL, diffuse large B-cell lymphoma.